C4 Therapeutics (CCCC) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 24.8% versus a gain of 11.6%. Over five years, ENTA leads with a -82.7% price change compared with -93.6% for CCCC. Enanta Pharmaceuticals is the larger company by market cap ($355.0 million vs $353.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | ENTA |
|---|---|---|
| Share price | $2.88 | $12.19 |
| Market cap | $353.70M | $355.04M |
| 1-day change | +1.95% | -1.46% |
| YTD return | +47.64% | -21.56% |
| 1-year return | +24.78% | +11.64% |
| 5-year return | -93.57% | -82.69% |
| EPS (TTM) | $-0.91 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $17.15 |
| 52-week low | $1.69 | $10.20 |
| Distance from 52-week high | -44.39% | -28.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +363.65% | +79.08% |
| Average volume | 2.38M | 226.58K |
| Shares outstanding | 123.03M | 29.13M |
| Employees | 104 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed ENTA by 13.1 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
CCCC vs ENTA FAQ
Which is bigger, C4 Therapeutics or Enanta Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $355.04M compared with $353.70M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or ENTA?
CCCC returned +24.78% over the past 12 months, compared with +11.64% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Enanta Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for C4 Therapeutics and Biotechnology: Pharmaceutical Preparations for Enanta Pharmaceuticals.